BackVertex Pharmaceuticals Overview
Vertex Pharmaceuticals, Inc.

Vertex Pharmaceuticals Target Price

See Vertex Pharmaceuticals's analyst price targets ($550) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$557.96

Average Target Price

$545.762.2% downside

17 analysts in the last 4 months

High: $617 | Low: $350

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-11BernsteinJeffrey Walch$6089% upsideOpen
2026-08-10Wolfe ResearchAndy Chen$5620.7% upsideOpen
2026-08-05Truist Financial$5651.3% upsideOpen
2026-08-05Barclays$61710.6% upsideOpen
2026-08-04Canaccord Genuity$44220.8% downsideOpen
2026-08-04Stifel Nicolaus$50010.4% downsideOpen
2026-08-04Cantor Fitzgerald$5956.6% upsideOpen
2026-07-13Truist Financial$5600.4% upsideOpen
2026-07-13UBS$5854.8% upsideOpen
2026-07-07RBC Capital$5702.2% upsideOpen
2026-07-07Robert W. Baird$35037.3% downsideOpen
2026-05-27Truist FinancialDanielle Brill$5422.9% downsideOpen
2026-05-06Barclays$61510.2% upsideOpen
2026-05-05RBC CapitalBrian Abrahams$5432.7% downsideOpen
2026-05-05Bernstein$5722.5% upsideOpen
2026-05-05Morgan Stanley$61610.4% upsideOpen
2026-05-05Canaccord Genuity$43621.9% downsideOpen
2026-04-30Canaccord Genuity$43721.7% downsideOpen
2026-04-10Morgan Stanley$6129.7% upsideOpen
2026-03-10JefferiesAkash Tewari$5804% upsideOpen
2026-03-10Truist FinancialJoon Lee$5255.9% downsideOpen
2026-03-02BMO CapitalEvan David Seigerman$6007.5% upsideOpen
2026-02-17BarclaysEliana Merle$6078.8% upsideOpen
2026-02-17Canaccord Genuity$44121% downsideOpen
2026-02-17H.C. WainwrightAndrew Fein$5915.9% upsideOpen
2026-02-13Cantor Fitzgerald$5905.7% upsideOpen
2026-02-13Bernstein$5773.4% upsideOpen
2026-02-13RBC Capital$5413% downsideOpen
2026-02-13ScotiabankLouise Chen$5580% upsideOpen
2026-02-13Stifel NicolausPaul Matteis$46616.5% downsideOpen
2026-02-13H.C. WainwrightAndrew Fein$5187.2% downsideOpen
2026-02-13Morgan StanleyTerence Flynn$5702.2% upsideOpen
2026-01-27Barclays$6068.6% upsideOpen
2026-01-26UBS$5452.3% downsideOpen
2026-01-23Evercore ISICory Kasimov$5305% downsideOpen
2026-01-22RBC CapitalBrian Abrahams$5462.1% downsideOpen
2026-01-06UBSMichael Yee$5354.1% downsideOpen
2025-12-29Leerink Partners$5255.9% downsideOpen
2025-12-05Morgan Stanley$5641.1% upsideOpen
2025-12-03Morgan StanleyTerence Flynn$5167.5% downsideOpen
2025-11-04Cantor FitzgeraldCarter Gould$48513.1% downsideOpen
2025-11-04BarclaysGena Wang$41425.8% downsideOpen
2025-11-04RBC Capital$41525.6% downsideOpen
2025-11-04Stifel Nicolaus$44520.2% downsideOpen
2025-10-10Morgan Stanley$43821.5% downsideOpen
2025-09-25Leerink Partners$45618.3% downsideOpen
2025-08-05BMO Capital$5305% downsideOpen
2025-08-05UBSEliana Merle$5530.9% downsideOpen
2025-08-05Stifel Nicolaus$45518.5% downsideOpen
2025-08-05Truist Financial$49012.2% downsideOpen

Vertex Pharmaceuticals (VRTX) FAQ

Vertex Pharmaceuticals posts a target price of $550. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $550 for VRTX means covering analysts, on average, see the stock 2.2% downside of $557.96 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for VRTX's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Vertex Pharmaceuticals's other metric pages and overview cover the third.

Judging Vertex Pharmaceuticals against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $550 here, then scan peer and history charts to see if the gap is persistent.